Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BNTX stock price vs PSTG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PSTG's multiple
Needs PSTG P/S.
Implied fair value · at BNTX's multiple
Needs BNTX P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · PSTG FY 2026 (ended Feb 1, 2026). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
BioNTech SE · implied price per share
Bear
-$6.81
Base
-$8.01
Bull
-$9.21
Everpure, Inc. · implied price per share
Bear
$6.64
Base
$7.81
Bull
$8.99
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.14x
Net debt / EBITDA
Leverage against operating earnings
4.45x
-4.58x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$1.60B
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
NetApp, Inc.
BNTX vs NTAP
Dell Technologies Inc.
BNTX vs DELL
INTERNATIONAL BUSINESS MACHINES CORP
BNTX vs IBM
Hewlett Packard Enterprise Co
BNTX vs HPE
QUANTUM CORP /DE/
BNTX vs QMCO
$200.00M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe BNTX can materially improve margins and earnings from the current low base, then hold or selectively add only on weakness because the stock already trades above PSTG-implied price and its quality metrics are currently poor.
BNTX’s current price of $97.57 is above PSTG implied price of $92.50, implying a modest -5.2% downside. On a relative basis, BNTX trades at 7.5x P/S versus PSTG at 7.2x, while BNTX’s EV/Revenue is lower at 5.8x versus 6.8x, so the valuation picture is not uniformly expensive.
Supporting Metrics
